14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ACAD ranks #12980 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

ACADIA Pharmaceuticals Inc. Stock Forecast NASDAQ:ACAD

$21.87 (4.44%)

Volume: 2M

Closed: Jan 19, 2022

Hollow Logo Score: -2.769

ACADIA Pharmaceuticals Inc. Stock Forecast

$21.87 (4.44%)

Volume: 2M

Closed: Jan 19, 2022

Score Hollow Logo -2.769

ACADIA Pharmaceuticals Inc. Company Profile

3611 Valley Centre Drive

San Diego CA 92130



Industry: Biotechnology

Sector: Healthcare

ACADIA Pharmaceuticals Inc.


ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer’s disease psychosis. It also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE